Shopping Cart
- Remove All
- Your shopping cart is currently empty
Mdivi-1 (Mitochondrial division inhibitor 1) is a mitochondrial division inhibitor that inhibits DRP1 and Dynamin I (IC50=1-10 μM). Mdivi-1 inhibits mitochondrial autophagy.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
5 mg | $39 | In Stock | |
10 mg | $51 | In Stock | |
25 mg | $92 | In Stock | |
50 mg | $155 | In Stock | |
100 mg | $239 | In Stock | |
200 mg | $355 | In Stock | |
500 mg | $588 | In Stock | |
1 mL x 10 mM (in DMSO) | $43 | In Stock |
Description | Mdivi-1 (Mitochondrial division inhibitor 1) is a mitochondrial division inhibitor that inhibits DRP1 and Dynamin I (IC50=1-10 μM). Mdivi-1 inhibits mitochondrial autophagy. |
Targets&IC50 | Dnm1 GTPase:1 μM-10 μM |
In vitro | In the ganglion cell layer (GCL), Mdivi-1 exhibits strong immunoreactivity. Twelve hours following ischemic induction, Mdivi-1 significantly increases protein expression within the GCL. It notably reduces the expression of GFAP protein without altering Drp1 protein expression. In the normal murine retina, Mdivi-1 primarily localizes to the inner plexiform layer, ganglion cell layer, outer plexiform layer, and inner nuclear layer. Early in the development of the ischemic murine retina, there is a marked increase in the protein expression of Mdivi-1 and glial fibrillary acidic protein (GFAP). Mdivi-1 inhibits apoptosis in the ischemic retina and significantly increases the survival rate of retinal ganglion cells (RGC) two weeks post-ischemia. |
In vivo | Mdivi-1 inhibits the ATPase activity and self-assembly of Dnm1 by inducing a conformational change (IC50<10 μM). It effectively suppresses C8-Bid and STS-induced mitochondrial outer membrane permeabilization (MOMP) in HeLa cells and extracellular mouse liver mitochondria. Mdivi-1 blocks the divisionof Dynamin-related GTPases, yeast Dnm1, and human Drp1, facilitating efficient and reversible mitochondrial fusion into a net-like structure. Intracellularly, it prevents apoptosis by inhibiting mitochondrial outer membrane permeabilization. Mdivi-1 represents a potential therapeutic class for treating stroke, myocardial infarction, and neurodegenerative diseases. |
Kinase Assay | All GTPase assay reactions are started in a 200 μL volume, of which 150 μL is placed into the well of a 96-well plate. Depletion of NADH, as monitored by reading the A340 of the reaction, is measured every 20 s for a total of 40 min using a SpectraMAX 250 96-well plate reader. Spectrophotometric data are transferred to Excel and the measured steady state depletion of NADH over time is converted to protein activity. |
Cell Research | Mdivi-1 is dissolved in DMSO. YPGlycerol plates are topped with 10 mL YPGlycerol containing 1% low melt agar and 75 μM mdivi-1, and cells are spotted 12 hours later using a 48 well pinning device. After pinning cells, plates are incubated at 24°C or 37°C and imaged using an Eagle Eye II imaging system. |
Alias | Mitochondrial division inhibitor 1 |
Molecular Weight | 353.22 |
Formula | C15H10Cl2N2O2S |
Cas No. | 338967-87-6 |
Smiles | O=C1N(C(=S)NC=2C1=CC=CC2)C3=CC(OC)=C(Cl)C=C3Cl |
Relative Density. | 1.57 g/cm3 (Predicted) |
Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
Solubility Information | DMSO: 50 mg/mL (141.55 mM), Sonication is recommended. ![]() | |||||||||||||||||||||||||||||||||||
In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 3.53 mg/mL (9.99 mM), suspension.In vivo: Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.![]() | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.